Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects

@article{Krystal2004PreliminaryEO,
  title={Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects},
  author={John H. Krystal and Walid Michel Abi-Saab and Edward B. Perry and Deepak Cyril D’Souza and N Liu and Ralitza Gueorguieva and Lisa McDougall and Tracy Hunsberger and Aysenil Belger and Louise R. Levine and Alan Breier},
  journal={Psychopharmacology},
  year={2004},
  volume={179},
  pages={303-309}
}
RationaleSome of the behavioral consequences of deficits in N-methyl-d-aspartate (NMDA) glutamate receptor function are thought to arise from the disinhibition of cortical glutamatergic circuitry.ObjectiveThis study evaluated whether pretreatment with a drug that reduces glutamatergic activation, the group II metabotropic glutamate receptor (mGluR) agonist, LY354740, reduced the cognitive effects of the NMDA glutamate receptor antagonist, ketamine, in healthy human subjects.MethodsNineteen… Expand
Attenuation of ketamine-induced impairment in verbal learning and memory in healthy volunteers by the AMPA receptor potentiator PF-04958242
TLDR
‘High-impact’ AMPAR potentiators like PF-04958242 may have a role in the treatment of the cognitive symptoms, but not the positive or negative symptoms, associated with schizophrenia. Expand
Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats.
TLDR
Data indicate that activation of mGlu2/3 receptors reduces the disruptive effects of NMDA receptor hypofunction on the spontaneous spike activity and bursting of PFC neurons, which may provide a physiological basis for reversal ofNMDA antagonist-induced behaviors by mGLU2/ 3 agonists. Expand
The interplay of cannabinoid and NMDA glutamate receptor systems in humans: Preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects
TLDR
Cannabidiol significantly augmented the activating effects of ketamine, as measured by the activation subscales of the BPRS, however, CBD showed a non-significant trend to reduce ketamine-induced depersonalization, as measures by the CADSS. Expand
The acute effects of NMDA antagonism: From the rodent to the human brain
TLDR
Evidence suggests that ketamine's effects are not restricted to pyramidal cells, but extend to GABAergic interneurons and the glia and other neurotransmitter systems are discussed, and increased extracellular glutamate levels following NMDA antagonist administration stand out as a well replicated finding. Expand
The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers
TLDR
This study characterizes the behavioral effects associated with ketamine and suggests that ketamine decreases verbal memory performance by interfering with early consolidation processes. Expand
Glycine Transporter Inhibitor Attenuates the Psychotomimetic Effects of Ketamine in Healthy Males: Preliminary Evidence
TLDR
This study demonstrates for the first time in humans that a GlyT1 inhibitor reduces the effects induced by NMDA receptor antagonism, and provides preliminary support for further study of the antipsychotic potential of GlyT 1 inhibitors. Expand
Prevention of ketamine-induced working memory impairments by AMPA potentiators in a nonhuman primate model of cognitive dysfunction
TLDR
The results support AMPA receptor potentiators as a potential adjunctive treatment for cognitive impairment associated with schizophrenia (CIAS) by finding that positive modulation of AMPA receptors robustly ameliorates ketamine-induced working memory impairments without altering behavioral effects of acute ketamine. Expand
Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats.
TLDR
The mixed effects of metabotropic glutamate receptor 2/3 agonism and antagonism on cognitive performance under baseline conditions and after disruption with phencyclidine demonstrate that different aspects of cognition may respond differently to a given pharmacological manipulation, indicating that potential antipsychotic or pro-cognitive medications need to be tested for their effects on a range of cognitive modalities. Expand
Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine
TLDR
Repeated exposure to ketamine did not result in increased behavioral responses, suggestive of behavioral sensitization, but evidence of sensitization to the behavioral effects of ketamine is not provided. Expand
Relationship of Resting Brain Hyperconnectivity and Schizophrenia-like Symptoms Produced by the NMDA receptor Antagonist Ketamine in Humans
TLDR
This study supports the hypothesis that pathological increases in resting brain functional connectivity contribute to the emergence of positive and negative symptoms associated with schizophrenia. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
Activation of Glutamatergic Neurotransmission by Ketamine: A Novel Step in the Pathway from NMDA Receptor Blockade to Dopaminergic and Cognitive Disruptions Associated with the Prefrontal Cortex
TLDR
The findings suggest that ketamine may disrupt dopaminergic neurotransmission in the PFC as well as cognitive functions associated with this region, in part, by increasing the release of glutamate, thereby stimulating postsynaptic non-NMDA glutamate receptors. Expand
Attenuation of Ketamine Effects by Nimodipine Pretreatment in Recovering Ethanol Dependent Men: Psychopharmacologic Implications of the Interaction of NMDA and L-Type Calcium Channel Antagonists
TLDR
Nimodipine reduced the capacity of ketamine to induce psychosis, negative symptoms, altered perception, dysphoria, verbal fluency impairment, and learning deficits, and these data suggest that drugs, such as ethanol, that combine NMDA and L-type VSCC antagonism may have enhanced tolerability without attenuation of their stimulant effects. Expand
Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.
TLDR
The hypothesis that lamotrigine, a drug reported to inhibit glutamate release, will reduce the neuropsychiatric effects of ketamine in humans is tested and it is suggested that glutamate release-inhibiting drugs may reduce the hyperglutamatergic consequences of NMDA receptor dysfunction implicated in the pathophysiologic processes of neuro psychological illnesses such as schizophrenia. Expand
NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers
TLDR
The effects of subanesthetic doses of ketamine on two forms of memory, free recall and recognition, as well as attention and behavior in 15 healthy volunteers are examined, suggesting that the NMDA receptor plays a direct role in two types of explicit memory. Expand
Therapeutic Implications of the Hyperglutamatergic Effects of NMDA Antagonists
Antagonists of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor produce transient effects in healthy human subjects that resemble symptoms observed in some schizophrenic patients. NMDAExpand
Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis
TLDR
This double-blind, placebo-controlled, randomized, within-subjects comparison of three fixed subanesthetic, steady-state doses of intravenous ketamine in healthy males demonstrated dose-dependent increases in Brief Psychiatric Rating Scale positive and negative symptoms. Expand
The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats.
TLDR
The marked mGlu2/3 receptor-mediated inhibitions of PCP-evoked behaviors by LY354740 and LY379268, with minimal effects on AMP, may indicate potential antipsychotic effects in humans in the absence of dopamine mediated extrapyramidal side effects. Expand
Effects of ketamine on sensory perception: evidence for a role of N-methyl-D-aspartate receptors.
TLDR
In healthy volunteers, the most obvious effect of subanesthetic doses of both enantiomers was altered sensory perception, and (S)-Ketamine was 4 times as potent as (R)-ketamine in reducing pain perception and in causing auditory and visual disturbances. Expand
Ketamine Increases Human Motor Cortex Excitability to Transcranial Magnetic Stimulation
TLDR
It is suggested that the enhancement of human motor cortex excitability to transcranial magnetic stimulation is the effect of an increase in glutamatergic transmission at non‐NMDA receptors similar to that described in experimental studies. Expand
Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.
TLDR
These data indicate that N-methyl-D-aspartate antagonists produce a broad range of symptoms, behaviors, and cognitive deficits that resemble aspects of endogenous psychoses, particularly schizophrenia and dissociative states. Expand
...
1
2
3
4
5
...